Pharmaceutical Executive-08-16-2005

This vaccine specialist is attempting to create a product that will protect people from influenza A for every future flu season without re-formulation. They are thinking about how to fight influenza B, too.

Migraine specialist abandons one problematic drug and maintains its position by filing an NDA the following week.

Only a year after the National Human Genome Research Institute called for improving sequencing technology, two new methods were announced in the same week. What will the goal of a $1000 human genome mean for medicine and disease research?